KIMATINIB LAUNCHING

Laboratorios Clausen S. A. announces the launching of KIMATINIB (Imatinib Mesilate).
Kimatinib is indicated for the treatment of Chronic Myeloid Leukemia patients of recent diagnosis.

Kimatinib is produced in the new High Technology Pharmaceutical facility of Laboratorios Clausen S.A. in Uruguay and undergoes severe quality control procedures through all the steps of production.

Kimatinib is supplied as:

KIMATINIB comp 100 mg

KIMATINIB comp 400 mg.